Luteolin and luteolin-7-O-glucoside protect against acute liver injury through regulation of inflammatory mediators and antioxidative enzymes in GalN/LPS-induced hepatitic ICR mice
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
BACKGROUND/OBJECTIVES: Anti-inflammatory and antioxidative activities of luteolin and luteolin-7-O-glucoside were compared in galactosamine (GalN)/lipopolysaccharide (LPS)-induced hepatitic ICR mice. MATERIALS/METHODS: Male ICR mice (6 weeks old) were divided into 4 groups: normal control, GalN/LPS, luteolin, and luteolin-7-O-glucoside groups. The latter two groups were administered luteolin or luteolin-7-O-glucoside (50 mg/kg BW) daily by gavage for 3 weeks after which hepatitis was induced by intraperitoneal injection of GalN and LPS (1 g/kg BW and 10 μg/kg BW, respectively). RESULTS: GalN/LPS produced acute hepatic injury by a sharp increase in serum AST, ALT, and TNF-α levels, increases that were ameliorated in the experimental groups. In addition, markedly increased expressions of cyclooxygenase (COX)-2 and its transcription factors, nuclear factor (NF)-κB and activator protein (AP)-1, were also significantly attenuated in the experimental groups. Compared to luteolin-7-O-glucoside, luteolin more potently ameliorated the levels of inflammatory mediators. Phase II enzymes levels and NF-E2 p45-related factor (Nrf)-2 activation that were decreased by GalN/LPS were increased by luteolin and luteolin-7-O-glucoside administration. In addition, compared to luteolin, luteolin-7-O-glucoside acted as a more potent inducer of changes in phase II enzymes. Liver histopathology results were consistent with the mediator and enzyme results. CONCLUSION: Luteolin and luteolin-7-O-glucoside protect against GalN/LPS-induced hepatotoxicity through the regulation of inflammatory mediators and phase II enzymes.
Abstract
BACKGROUND/OBJECTIVES: Anti-inflammatory and antioxidative activities of luteolin and luteolin-7-O-glucoside were compared in galactosamine (GalN)/lipopolysaccharide (LPS)-induced hepatitic ICR mice. MATERIALS/METHODS: Male ICR mice (6 weeks old) were divided into 4 groups: normal control, GalN/LPS, luteolin, and luteolin-7-O-glucoside groups. The latter two groups were administered luteolin or luteolin-7-O-glucoside (50 mg/kg BW) daily by gavage for 3 weeks after which hepatitis was induced by intraperitoneal injection of GalN and LPS (1 g/kg BW and 10 μg/kg BW, respectively). RESULTS: GalN/LPS produced acute hepatic injury by a sharp increase in serum AST, ALT, and TNF-α levels, increases that were ameliorated in the experimental groups. In addition, markedly increased expressions of cyclooxygenase (COX)-2 and its transcription factors, nuclear factor (NF)-κB and activator protein (AP)-1, were also significantly attenuated in the experimental groups. Compared to luteolin-7-O-glucoside, luteolin more potently ameliorated the levels of inflammatory mediators. Phase II enzymes levels and NF-E2 p45-related factor (Nrf)-2 activation that were decreased by GalN/LPS were increased by luteolin and luteolin-7-O-glucoside administration. In addition, compared to luteolin, luteolin-7-O-glucoside acted as a more potent inducer of changes in phase II enzymes. Liver histopathology results were consistent with the mediator and enzyme results. CONCLUSION: Luteolin and luteolin-7-O-glucoside protect against GalN/LPS-induced hepatotoxicity through the regulation of inflammatory mediators and phase II enzymes.
참고문헌 (37)
- Fei J, "Luteolin inhibits IL-1β-induced inflammation in rat chondrocytes and attenuates osteoarthritis progression in a rat model", Biomed Pharmacother, 109, pp.1586~1592 (2019)
- Seelinger G, "Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin", Planta Med, 74, pp.1667~1677 (2008)
- Richelle M, "Hydrolysis of isoflavone glycosides to aglycones by beta-glycosidase does not alter plasma and urine isoflavone pharmacokinetics in postmenopausal women", J Nutr, 132, pp.2587~2592 (2002)
- Izumi T, "Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans", J Nutr, 130, pp.1695~1699 (2000)
- Kano M, "Bioavailability of isoflavones after ingestion of soy beverages in healthy adults", J Nutr, 136, pp.2291~2296 (2006)
- Andlauer W, "Isoflavones from tofu are absorbed and metabolized in the isolated rat small intestine", J Nutr, 130, pp.3021~3027 (2000)
- Rowland I, "Bioavailability of phyto-oestrogens", Br J Nutr, 89(Suppl 1), pp.S45~S58 (2003)
- Kure A, "Metabolic fate of luteolin in rats: its relationship to anti-inflammatory effect", J Agric Food Chem, 64, pp.4246~4254 (2016)
- Zhou P, "Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin", J Agric Food Chem, 56, pp.296~300 (2008)
- Piskula MK, "Factors affecting flavonoids absorption", Biofactors, 12, pp.175~180 (2000)
- Zubik L, "Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women", Am J Clin Nutr, 77, pp.1459~1465 (2003)
- Kemelo MK, "D-galactosamine", lipopolysaccharide-induced hepatotoxicity downregulates sirtuin 1 in rat liver: role of sirtuin 1 modulation in hepatoprotection, 2014, pp.63, 615~623
- Ferencíková R, "Hepatotoxic effect of D-galactosamine and protective role of lipid emulsion", Physiol Res, 52, pp.73~78 (2003)
- Surh YJ, "Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation", Mutat Res, 480-481, pp.243~268 (2001)
- Fujioka S, "NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity", Mol Cell Biol, 24, pp.7806~7819 (2004)
- Sajadimajd S, "Oxidative stress and cancer: the role of Nrf2", Curr Cancer Drug Targets, 18, pp.538~557 (2018)
- Zhang M, "Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection", Prog Neurobiol, 100, pp.30~47 (2013)
- Mao J, "Protective effects of costunolide against D-galactosamine and lipopolysaccharide-induced acute liver injury in mice", Front Pharmacol, 9, pp.1469~ (2018)
- Aziz N, "Anti-inflammatory effects of luteolin: a review of in vitro, in vivo, and in silico studies", J Ethnopharmacol, 225, pp.342~358 (2018)
- Jia Z, "Luteolin protects against vascular inflammation in mice and TNF-alpha-induced monocyte adhesion to endothelial cells via suppressing IΚBα", NF-κB signaling pathway, 2015, pp.26, 293~302
- 박충무, "Luteolin and luteolin-7-O-glucoside inhibit lipopolysaccharide-induced inflammatory responses through modulation of NF-κB", AP-1, Nutrition Research and Practice, pp.2013, 7(6)[DOI]
- Song YS, "Luteolin and luteolin-7-O-glucoside strengthen antioxidative potential through the modulation of Nrf2", MAPK mediated HO-1 signaling cascade in RAW 264.7 cells, 2014, pp.65, 70~75
- Lee WC, "Protective effects of luteolin against apoptotic liver damage induced by D-galactosamine", lipopolysaccharide in mice, 2011, pp.74, 1916~1921
- Hossen MJ, "Thymoquinone: an IRAK1 inhibitor with in vivo and in vitro anti-inflammatory activities", Sci Rep, 7, pp.42995~ (2017)
- Wu YH, "Nature and mechanisms of hepatocyte apoptosis induced by D-galactosamine", lipopolysaccharide challenge in mice, 2014, pp.33, 1498~1506
- Shanmugam S, "Effects of luteolin and quercetin 3-β-d-glucoside identified from Passiflora subpeltata leaves against acetaminophen induced hepatotoxicity in rats", Biomed Pharmacother, 83, pp.1278~1285 (2016)
- Jiang W, "Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll-like receptor 4 expression on macrophages", Proc Natl Acad Sci U S A, 102, pp.17077~17082 (2005)
- Nowak M, "LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-α and the TNF-p55 receptor", Am J Physiol Regul Integr Comp Physiol, 278, pp.R1202~R1209 (2000)
- Hossen MJ, "AP-1-targeted inhibition of macrophage function and lipopolysaccharide", D-galactosamineinduced hepatitis by Phyllanthus acidus methanolic extract, 2015, pp.43, 1137~1158
- Dejager L, "Tumor necrosis factor alpha mediates the lethal hepatotoxic effects of poly(I:C) in D-galactosamine-sensitized mice", Cytokine, 42, pp.55~61 (2008)
- Kim YW, "Inflammation and oxidative stress in angiogenesis and vascular disease", J Mol Med (Berl), 91, pp.323~328 (2013)
- Lee JP, "Protective effects of luteolin against lipopolysaccharide-induced acute lung injury involves inhibition of MEK", ERK and PI3K, Acta Pharmacol Sin, pp.2010, 31[DOI]
- 박충무, "Luteolin Inhibits Inflammatory Responses by Downregulating the JNK, NF-κB, and AP-1 Pathways in TNF-α Activated HepG2 Cells", Food Science and Biotechnology, 21(1), pp.279~283 (2012), 한국식품과학회
- Shimoi K, "Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans", FEBS Lett, 438, pp.220~224 (1998)
- Murota K, "Unique uptake and transport of isoflavone aglycones by human intestinal caco-2 cells: comparison of isoflavonoids and flavonoids", J Nutr, 132, pp.1956~1961 (2002)
- Hollman PC, "Health effects and bioavailability of dietary flavonols", Free Radic Res, 31(Suppl), pp.S75~S80 (1999)
- Ross JA, "Dietary flavonoids: bioavailability, metabolic effects, and safety", Annu Rev Nutr, 22, pp.19~34 (2002)